High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug responseHui Gao, Zongyao Wang, Audrey Kauffmann et al.|Nature Medicine|2015Cited by 1.4k
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Mallika Singh, Elena S. Koltun et al.|Nature|2024Cited by 319
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Mallika Singh|Cancer Discovery|2024Cited by 267
Proapoptotic Activation of Death Receptor 5 on Tumor Endothelial Cells Disrupts the Vasculature and Reduces Tumor GrowthNicholas S. Wilson, Avi Ashkenazi, Annie Yang et al.|Cancer Cell|2012Cited by 61
A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, G. Leslie Burnett et al.|Science|2025Cited by 31